Mirati Therapeutics 관리

관리 기준 확인 3/4

Mirati Therapeutics CEO는 Chuck Baum, Nov2012 에 임명되었습니다 의 임기는 11.17 년입니다. 총 연간 보상은 $ 7.42M, 9.2% 로 구성됩니다. 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함). 는 R$ 32.75M 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 32.75M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 5.1 년입니다.

주요 정보

Chuck Baum

최고 경영자

US$7.4m

총 보상

CEO 급여 비율	9.2%
CEO 임기	11.2yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	5.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chuck Baum 의 보수는 Mirati Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$726m
Jun 30 2023	n/a	n/a	-US$738m
Mar 31 2023	n/a	n/a	-US$737m
Dec 31 2022	US$7m	US$685k	-US$741m
Sep 30 2022	n/a	n/a	-US$738m
Jun 30 2022	n/a	n/a	-US$645m
Mar 31 2022	n/a	n/a	-US$634m
Dec 31 2021	US$18m	US$662k	-US$582m
Sep 30 2021	n/a	n/a	-US$483m
Jun 30 2021	n/a	n/a	-US$491m
Mar 31 2021	n/a	n/a	-US$407m
Dec 31 2020	US$12m	US$615k	-US$358m
Sep 30 2020	n/a	n/a	-US$329m
Jun 30 2020	n/a	n/a	-US$296m
Mar 31 2020	n/a	n/a	-US$259m
Dec 31 2019	US$8m	US$597k	-US$213m
Sep 30 2019	n/a	n/a	-US$169m
Jun 30 2019	n/a	n/a	-US$142m
Mar 31 2019	n/a	n/a	-US$125m
Dec 31 2018	US$5m	US$580k	-US$98m
Sep 30 2018	n/a	n/a	-US$88m
Jun 30 2018	n/a	n/a	-US$77m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$2m	US$563k	-US$70m

보상 대 시장: Chuck 의 총 보상 ($USD 7.42M )은 BR 시장( $USD 1.29M ).

보상과 수익: Chuck 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chuck Baum (65 yo)

11.2yrs

테뉴어

US$7,420,213

보상

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
James Christensen	Executive VP & Chief Scientific Officer	10yrs	US$5.01m	0.082% R$ 16.8m
Alan Bart Sandler	Executive VP & Chief Medical Officer	1.2yrs	US$5.30m	0.014% R$ 2.9m
Aaron Ondrey	Chief Financial Officer	less than a year	데이터 없음	0.056% R$ 11.5m
Betsy Gelfand	Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
John Moriarty	Chief Legal Officer & Corporate Secretary	less than a year	데이터 없음	데이터 없음
Peter Lee	Chief Compliance Officer	2yrs	데이터 없음	데이터 없음
Michael Paolucci	Chief People Officer	2yrs	데이터 없음	데이터 없음
Benjamin Hickey	Chief Commercial Officer	4yrs	US$6.93m	0.040% R$ 8.1m
Kelly Covello	VP & Head of Medical Affairs	3.8yrs	데이터 없음	데이터 없음
Ryan Asay	VP & Head of Corporate Affairs	3.8yrs	데이터 없음	데이터 없음
Susan Welsh	Senior VP of Pharmacovigilance & Chief Safety Officer	3yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: M2RT34 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
Bruce Leonard Carter	Independent Director	7.3yrs	US$700.41k	0.0086% R$ 1.8m
George Demetri	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Faheem Hasnain	Chairman & Lead Independent Director	4.9yrs	US$979.79k	0.012% R$ 2.6m
Julie Michele Cherrington	Independent Director	4.6yrs	US$697.91k	0% R$ 0
Stephen Baylin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lillian Siu	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Aaron Davis	Independent Director	5.1yrs	US$677.91k	0.061% R$ 12.6m
Pasi Antero Janne	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Craig Johnson	Independent Director	10.3yrs	US$702.91k	0.0086% R$ 1.8m
Channing Der	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Maria Martinez-Davis	Independent Director	5.1yrs	US$695.41k	0.0086% R$ 1.8m

5.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: M2RT34 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Mirati Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령